Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies

Thyroid

Volumn 18, Issue 7, 2008, Pages 809-812

  Alexandrescu, Doru T ^a   Popoveniuc, Geanina ^e   Farzanmehr, Haleh ^b   Dasanu, Constantin A ^c   Dawson, Nancy ^d   Wartofsky, Leonard ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c Group Health   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; SORAFENIB; SUNITINIB; THYROID ANTIBODY; THYROID HORMONE;

ADULT; ANASARCA; ASPIRATION BIOPSY; BRAIN DAMAGE; CASE REPORT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LABORATORY TEST; LETTER; LYMPHOCYTIC THYROIDITIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; THYROID FUNCTION TEST; THYROID HORMONE RELEASE; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; THYROID GLAND; THYROIDITIS, AUTOIMMUNE; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 47549084773     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0349     Document Type: Letter

References (15)

1. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896.
2. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605.
3. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337.
4. Shaheen PE, Tamaskar IR, Salas RN 2006 Thyroid function tests (TFTs) abnormalities in patients with metastatic renal cell carcinoma (mRCC) in patients treated with sunitinib. Abstract presented at ASCO Annual Meeting, Atlanta, GA. J Clin Oncol 24:4605.
5. Schoeffski P, Wolter P, Himpe U 2006 Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. ASCO Proceedings. J Clin Oncol 18S:3092.
6. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664.
7. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83.
8. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355.
9. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534.
10. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35.
11. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:560-576.
12. Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA 1992 Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 24:434-438.
13. Kung AWC, Ma L, Lau KS 1992 The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture. Clin Exp Immunol 87:261-265.
14. Kung AWC, Lau KS 1990 Interferon-gamma inhibits thyrotropin-induced thyroglobulin gene transcription in cultured human thyrocytes. J Clin Endocrinol Metab 70: 1512-1517.
15. Baker JR, Saunders NA, Tseng Y-C, Wartofsky L, Ahmann A, Burman KD 1988 Seronegative Hashimoto thyroiditis with thyroid autoantibody production localized to the thyroid. Ann Intern Med 108:26-30.